A treatment for Huntington’s disease is judged partly on whether someone can still manage their finances, do the housework, or keep working. These are wonderfully unglamorous ambitions. They are also the point. Prilenia has built its company around an oral drug candidate intended to protect the machinery that lets neurons keep functioning. The scientific proposal is attractive. The clinical verdict remains unfinished.
- Prilenia develops pridopidine for Huntington’s disease and ALS.
- Earlier trials missed their main efficacy endpoints.
- A Ferrer partnership funds development and divides future commercial rights.
- Two new Phase 3 studies began in 2026; the medicine remains unapproved.
Money, partners and experienced executives cannot settle the central question: does the medicine help? Prilenia is useful to examine because its promise, disappointment and next experiment are all visible.
A capsule with an unusually large assignment
Founded in 2018 by physician-scientist Michael R. Hayden, Prilenia is a private biopharmaceutical business focused on neurodegenerative disease. Hayden previously led global research and development at Teva. His company brings together neuroscience, clinical development and regulatory expertise, with operations spanning North America, Europe and Israel. Its mission includes developing medicines and providing sustainable access to them.
Pridopidine is its lead asset: an investigational capsule taken twice daily that activates the sigma-1 receptor. This protein regulates cellular processes important to neuronal health. Prilenia’s hypothesis is that activating it can support protective pathways disrupted in Huntington’s disease and amyotrophic lateral sclerosis, or ALS.
The proposed biology involves energy production, disposal of toxic proteins and responses to cellular stress. Animal and cell studies support further investigation. Translating those findings into preserved human function is the difficult crossing. A neuron surviving in an experimental model cannot tell us whether a person will retain independence.
That approach gives Prilenia a particular place in the market. Huntington’s research also includes uniQure’s AMT-130 gene therapy and huntingtin-focused programs from other developers. Prilenia is pursuing protective cellular mechanisms with an oral small molecule. Different mechanisms and delivery methods create different practical possibilities; they do not, by themselves, establish which treatment works.
The result that would not cooperate
In PROOF-HD, 499 participants were randomized to pridopidine or placebo. The Phase 3 trial missed both its primary and key secondary endpoints in the overall population. Its principal measure, Total Functional Capacity, examines everyday independence. At 65 weeks, the drug had not demonstrated the required overall advantage.
Analyses involving participants who remained off antidopaminergic medicines showed patterns favoring pridopidine. Those findings sustained interest, but subgroup results after a failed primary endpoint require caution. They supplied a question for further research, rather than a settled clinical answer.
A large trial. Main efficacy endpoints missed. A reason to inspect the evidence carefully.
The European regulatory process supplied another boundary. EMA recommended refusing the Huntington’s marketing application in July 2025. Prilenia withdrew it on November 7. The proposed indication had narrowed to early Huntington’s disease in adults not taking antidopaminergic medicines. The medicine did not receive authorization.
The ALS program had its own disappointment: pridopidine’s HEALEY platform regimen missed its primary endpoint. Prilenia subsequently pursued a more specific population. The company’s continuing belief is understandable as a research position. Patients still need the next controlled experiment to deliver an answer.
€500 million, with conditions attached
Developing that answer requires capital. A $62.5 million Series A in 2020 supported late-stage trials. A $43 million Series B followed in 2021, then an additional $10 million from SV Health Investors in 2022. Backers financed experiments whose commercial payoff depended on future evidence.
In April 2025, Prilenia licensed pridopidine to Ferrer for Europe and other selected markets. The agreement specified approximately €80 million upfront, up to €45 million in near-term milestones, and an eventual total of up to approximately €500 million in upfront and milestone payments. Tiered double-digit royalties would follow future net sales.
Ferrer also shares development work and funding within the licensed territory. Prilenia retains rights in North America, Japan and Asia Pacific. This is its business model in concrete form: finance research, organize clinical evidence and allocate potential commercial rights. Ferrer is a business counterparty; patients are the intended beneficiaries of a medicine still being tested.
Two new studies, sharper questions
In March 2026, Prilenia and Ferrer announced the first participant enrolled in PREVAiLS. The planned 500-participant ALS study targets early, rapidly progressive disease. Its design seeks to confirm findings from a similar subgroup in the earlier program, with outcomes covering function and additional measures such as speech and survival.
PRECISE-HD began US recruitment in July. It plans to enroll 400 participants and operate at up to 75 sites globally. The study focuses on early to mid-stage Huntington’s disease with specified motor and independence criteria. Its design incorporates prior research and input from regulators, researchers and the patient community.
The distinction is consequential: recruitment targets describe the intended experiments, not completed enrollment or favorable results. In September, Prilenia appointed neurologist Rick Munschauer as chief medical officer. His stated priority includes “generating the evidence regulators need.” It is a pleasingly practical description of the job.
“generating the evidence regulators need”Rick Munschauer, Chief Medical Officer / September 2026
Even placebo gets another job
Prilenia’s collaborations extend beyond its licensed medicine. In May 2026, it agreed to provide CHDI Foundation with anonymized individual-level placebo data from its PRIDE and PROOF studies. CHDI can use the information for research and make it available to qualified third parties under the agreement.
Understanding placebo-related effects could improve future trial design and interpretation. The transaction also gives substance to Prilenia’s public emphasis on collaboration. A company’s recruiting language is easy to polish; sharing a useful dataset is a more concrete act.
What to do with an unfinished medicine
For patients and families, Prilenia currently offers research information and routes to investigate trial participation. Eligibility and recruitment vary by study and site; a treating clinician can help assess the relevant criteria. The company’s capsule remains investigational, with access governed by study or authorized access arrangements.
For other researchers, the transferable lesson is methodological: sharpen a hypothesis, test it prospectively, and preserve data that can help the next experiment. That approach needs adequate funding, suitable participants and measurements capable of detecting meaningful change. If the new controlled studies fail to demonstrate benefit, the elegant mechanism and the licensing economics cannot repair the result.
The interview predates the European decision and the 2026 trial launches.